The 5 most recent market catalysts affecting $CADL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Candel Therapeutics shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $12 to $18.
This headline represents a significant corporate catalyst for Candel Therapeutics. Analyst upgrades from major institutions like BofA Securities often lead to increased investor co…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18
B of A Securities analyst Alec Stranahan upgraded Candel Therapeutics (CADL) from Neutral to Buy and raised the price target from $12 to $18. This upgrade reflects a more optimisti…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
The filing indicates that HC Wainwright & Co. analyst Andres Y. Maldonado has reaffirmed a 'Buy' rating and a $23 price target for Candel Therapeutics. This action signals continue…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 95
Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate
Candel Therapeutics (CADL) reported a Q2 EPS of $(0.52), missing analyst estimates of $(0.23) by a substantial 126.09%. This significant earnings miss, coupled with a 477.78% incre…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22
Stifel analyst Stephen Willey has initiated coverage on Candel Therapeutics (CADL) with a 'Buy' rating and a $22 price target. This event is significant for CADL as it introduces n…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.